Target type: biologicalprocess
The process in which a mesenchymal cell, acquires specialized structural and/or functional features of a chondroblast. Differentiation includes the processes involved in commitment of a cell to a chondroblast fate. A chondroblast is a precursor cell to chondrocytes. [GOC:dph]
Chondroblast differentiation is a complex process involving a series of molecular events that ultimately lead to the formation of chondrocytes, the specialized cells responsible for producing and maintaining cartilage. This process begins with mesenchymal stem cells (MSCs) residing within the developing skeletal tissues. These undifferentiated cells have the potential to give rise to various cell types, including chondrocytes.
The initiation of chondroblast differentiation is driven by specific signaling molecules and transcription factors. These molecules, including bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), and transforming growth factor beta (TGF-beta), bind to receptors on the surface of MSCs, triggering a cascade of intracellular signaling events. These events activate specific transcription factors like Sox9, which act as master regulators of chondrogenesis.
Sox9 plays a crucial role in driving the expression of key genes involved in chondroblast differentiation, including Col2a1 and Aggrecan. Col2a1 encodes for type II collagen, the primary structural protein of cartilage, while Aggrecan is a large proteoglycan that contributes to the resilience and compressibility of the extracellular matrix. The expression of these genes marks the commitment of MSCs to the chondrocyte lineage.
As chondroblast differentiation progresses, the cells undergo morphological changes. They become rounded and exhibit increased expression of chondrocyte-specific markers. These changes are accompanied by the accumulation of a specialized extracellular matrix, rich in type II collagen, aggrecan, and other cartilage-specific components. This matrix provides structural support and allows for the diffusion of nutrients and waste products within the developing cartilage tissue.
Chondroblasts actively synthesize and deposit the extracellular matrix, contributing to the growth and expansion of the cartilage. As the cells mature, they become embedded within the matrix and transition into mature chondrocytes. These mature chondrocytes continue to maintain the integrity of the cartilage by synthesizing and degrading matrix components.
The differentiation of chondroblasts is influenced by a variety of factors, including mechanical forces, oxygen tension, and the presence of growth factors. Understanding the molecular mechanisms underlying chondroblast differentiation is crucial for developing therapeutic strategies for cartilage regeneration and treating cartilage-related diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Retinoic acid receptor alpha | A retinoic acid receptor alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:P10276] | Homo sapiens (human) |
Fibroblast growth factor 2 | A fibroblast growth factor 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09038] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
am 580 | 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist. Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source | amidobenzoic acid; tetralins | antineoplastic agent; retinoic acid receptor alpha/beta agonist |
bms 961 | BMS 961: a retinoic acid receptor gamma agonist; no further info available 10/2006 | ||
lg 100268 | LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source | ||
tazarotene | tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. tazarotene: a topical acetylenic retinoid; a topical kerytolytic | acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane | keratolytic drug; prodrug; teratogenic agent |
adapalene | adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether. Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE. | adamantanes; monocarboxylic acid; naphthoic acid | dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
tamibarotene | tamibarotene : A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine. tamibarotene: has retinoid-binding activity | dicarboxylic acid monoamide; retinoid; tetralins | antineoplastic agent; retinoic acid receptor alpha/beta agonist |
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid | |||
cd 437 | CD 437: selective for retinoic acid receptors gamma CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells. | adamantanes; monocarboxylic acid; naphthoic acid; phenols | apoptosis inducer; retinoic acid receptor gamma agonist |
6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid | 6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid: reverses keratinization process in hamster tracheal organ culture; inhibits induction of ornithine decarboxylase; structure & RN given in first source; RN not in Chemline 12/5/83 | ||
cd 2019 | CD 2019: a retinoic acid receptor beta2 agonist; structure given in first source | ||
agn 193109 | AGN 193109: structure given in first source | ||
tretinoin | all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). | retinoic acid; vitamin A | anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule |
bms 195614 | BMS 195614 : A carboxamide resulting from the formal condensation of the carboxy group of 5,5-dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalene-2-carboxylic acid with the amino group of p-aminobenzoic acid. It is a neutral retinoic acid receptor (RAR) alpha-selective antagonist (Ki = 2.5 nM). It displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. It antagonizes agonist-induced coactivator (CoA) recruitment. | benzoic acids; quinolines; secondary carboxamide | retinoic acid receptor alpha antagonist |
bms 961 | |||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
ac 55649 | 4'-octyl-4-biphenylcarboxylic acid: an RAR beta2 agonist; structure in first source | biphenyls; carboxybiphenyl | |
sr 11217 | SR 11217: structure given in first source | ||
lg 100567 | ALRT 1550: ALRT1550 is (2E,4E,6E)-isomer; LG100567 is (2E,4E,6Z)-isomer; structure given in first source | ||
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid: RN refers to (E)-isomer; structure given in first source arotinoid acid : A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR). | benzoic acids; naphthalenes; retinoid | antineoplastic agent; retinoic acid receptor agonist; teratogenic agent |
agn 191659 | AGN 191659: a retinoid x receptor pan-agonist; structure in first source | ||
agn 191701 | AGN 191701: retinoid X receptors agonist; RN refers to (E)-isomer; structure given in first source | ||
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
agn 190121 | |||
lg100754 | LG 100754: retinoic acid receptors antagonist & agonist; a mixed function retinoid whose activity is dimer-selective; structure given in first source | ||
lg 1506 | |||
nrx 194204 | IRX4204: retinoid X receptor (RXR) agonist; structure in first source | ||
agn 194204 | AGN 194204: a retinoid X receptor ligand; structure in first source | ||
bms453 | BMS 189453: structure in first source BMS-453 : A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). It is a potent retinoic acid receptor gamma (RARbeta) agonist that acts as an antagonist against RARalpha and RARgamma. | benzoic acids; dihydronaphthalenes; stilbenoid | retinoic acid receptor alpha antagonist; retinoic acid receptor beta agonist; retinoic acid receptor gamma antagonist; teratogenic agent |
hx 630 | HX 630: a retinoid X receptor ligand that functions as both an RAR synergist and peroxisome proliferator-activated receptor gamma synergist; structure in first source | ||
bms 204493 | BMS-493 : A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenylethynyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). | acetylenic compound; benzoic acids; dihydronaphthalenes; stilbenoid | retinoic acid receptor antagonist |
tivozanib | N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source | aromatic ether | |
sr 11302 | SR 11302: structure given in first source SR11302 : A retinoid that is all-trans-retinoic acid in which the methyl group at position 9 is replaced by a 4-methylphenyl group. It is an inhibitor of activator protein-1 which exhibits antitumour effects in vivo. | alpha,beta-unsaturated monocarboxylic acid; retinoid; toluenes | antineoplastic agent; AP-1 antagonist |
cd 666 | |||
agn 190205 | AGN 190205: inhibits vascular smooth muscle cell proliferation; structure in first source | ||
le 135 | LE 135: structure given in first source | dibenzodiazepine | |
ac 261066 | |||
phosphomannopentaose sulfate | phosphomannopentaose sulfate: structure in first source | ||
pg 545 | PG 545: an anti-angiogenesis agent with heparanase inhibitory activity; structure in first source |